| Literature DB >> 27397458 |
Klaus Gorlinger1, Vandana Bhardwaj2, Poonam Malhotra Kapoor2.
Abstract
Computer simulations can come in handy to train medical personnel with necessary skills to face the clinical scenarios involving various coagulopathies. Now a days, point of care (POC) devices such as thromboelastography, Sonoclot analyzer and newly approved rotational thromboelastometry (ROTEM) with faster results to assess coagulopathies are available on bedside of patients. ROTEM is emerging as a quick, portable, and well-validated device to evaluate coagulopathy in critical care and perioperative setup. A novel platelet-aggregometry integrated module enables simultaneous analysis of platelets as well as coagulation tests on the same screen. The entire gamut of POC signature curves obtained with different coagulation defects can be learned with graphical simulations. These simulations can be a valuable strategy to elucidate latent conditions, for which simulation interventions can then be designed to mimic different clinical scenarios.Entities:
Mesh:
Year: 2016 PMID: 27397458 PMCID: PMC4971982 DOI: 10.4103/0971-9784.185546
Source DB: PubMed Journal: Ann Card Anaesth ISSN: 0971-9784
Figure 1ROTEM device with integrated platelet-aggregometry module. ROTEM device containing 4 independendent channels in lower pannel for carrying out simultaneous different ROTEM tests (INTEM/EXTEM/FIBTEM/HEPTEM) and 2 channels in upper pannel for impedence aggregometry tests. ROTEM platelet assays (ARATEM/ADPTEM/TRAPTEM) are used to study effect on various platelet inhibior drugs. ROTEM: Rotational thromboelastometry
Various rotational thromboelastometry tests with different reagents
| ROTEM tests | Reagents used | Description |
|---|---|---|
| EXTEM | Tissue factor activator | Coagulation is activated by small amount of tissue factor to monitor coagulation via extrinsic pathway |
| INTEM | Ellagicacid/phospholipid activator | Coagulation is activated by contact phase to monitor coagulation via intrinsic pathway |
| HEPTEM | Heparinase in combination with INTEM | Comparison of HEPTEM with INTEM parameters can help in detection of heparinrelated coagulation disturbances |
| FIBTEM | Cytochalasin D in combination with EXTEM | Coagulation is activated as in EXTEM after neglecting platelet contribution to the clot firmness |
| APTEM | Aprotinin, fibrinolysis inhibitor in combination with EXTEM | Coagulation is activated as in EXTEM to monitor the clot firmness after blocking hyperfibrinolysis by aprotinin |
| ECATEM | Ecarin (prothrombin activator) | Diagnose direct thrombin inhibitor |
| NATEM | Activated by recalcification only | Sensitive to detect endogenous activators like tissue factor expression on monocytes cells in sepsis, extracorporeal device use, cirrhosis |
ROTEM: Rotational thromboelastometry
Figure 2Different ROTEM graphs with various reagents. Various ROTEM tests like (a) EXTEM (activator, tissue factor with polybrene); APTEM (EXTEM plus activator, aprotinin, or tranexamic acid) (b) FIBTEM (EXTEM plus activator, cytochalasin D) (c) INTEM (activator, ellagic-acid) (d) HEPTEM (INTEM plus activator heparinase) and ECATEM (activator, ecarin) are possible simultaneously with the use of different reagents. ROTEM: Rotational thromboelastometry
Figure 3Variables of ROTEM in TEMogram. The graphical representation (TEMogram) of clot amplitude (mm) against time (min) showing various ROTEM variables. ROTEM: Rotational thromboelastometry. TEMogram: Thromboelastometer-graphs
Rotational thromboelastometry variables derived from thromboelstometer graph
| ROTEM variable | Description |
|---|---|
| CT: Clotting time (s) | Time until the recognizable start of clot formation (2 mm amplitude) |
| CFT: Clot formation time (s) | Time until amplitude of 20 mm is reached. Represents the clot formation dynamics |
| Angle: Alpha-angle (°) | Angle between central line and a tangent to the curve through the 2 mm amplitude point. Represents the kinetics of clot formation |
| MCF: Maximum clot firmness (mm) | Maximum firmness (amplitude) that the clot achieves during the measurement |
| A10-A30: Amplitude at 10-30 min after CT (mm) | Describes the clot firmness at 10-30 min after CT |
| CL30: Clot lysis index at 30 min after CT (%) | Ratio between the MCF and the amplitude 30-60 min after CT. Describes the progress of fibrinolysis |
| ML: Maximal clot lysis (%) | Ratio of the lowest amplitude detected after achieving MCF to the MCF |
The reference values of thromboelastometer variables with differents rotational thromboelastometry tests in a multicentre study[
| CT (s) | CFT (s) | MCF (mm) | A10 (mm) | CL 30 (%) | ML (%) | |
|---|---|---|---|---|---|---|
| INTEM | 137-246 | 40-100 | 52-72 | 44-68 | 94-100 | 0-12 |
| EXTEM | 42-74 | 46-148 | 49-71 | 43-65 | 95-100 | 0-18 |
| FIBTEM | 43-69 | - | 9-25 | 9-24 | - | - |
CT: Clot time, CFT: Clot formation time, MCF: Maximum clot firmness, A10: Amplitude 10 min after CT, CL30: Clot lysis index 30 min after CT, ML: Maximal clot lysis
Various rotational thromboelastometry platelet assays[
| ROTEM platelet assays | Reagents used | Description |
|---|---|---|
| ARATEM | Arachidonic acid | Studies COX-1 and GP IIb/IIIa receptors inhibition |
| ADPTEM | ADP | Studies ADP and GP IIb/IIIa receptors inhibition |
| TRAPTEM | Thrombin receptor activating peptide-6 | Studies Thrombin and GPII/bIIIa receptors inhibition |
COX: Cyclooxygenase, GP: Glycoprotein, ADP: Adenosine diphosphate, ROTEM: Rotational thromboelastometry, TEM: Thromboelastometry